Apollomics Inc. is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing innovative therapies to treat cancer. The company’s research pipeline spans multiple modalities, including small molecules, monoclonal antibodies and bispecific therapeutics, designed to address key pathways in tumor growth and immune evasion. Apollomics applies a precision medicine approach by targeting specific genetic and immune biomarkers to enhance efficacy and minimize off‐target effects in patients with solid tumors and hematologic malignancies.
Among its lead assets is APG-115, an MDM2 inhibitor being evaluated for advanced solid tumors and lymphomas, and APG-1252AA1, a BCL-2/BCL-XL inhibitor in development for lymphoid and myeloid cancers. The company’s pipeline also includes APG-2449, a next‐generation kinase inhibitor targeting FGFR and EGFR mutations, and additional antibody‐drug conjugates aimed at hard‐to-treat tumor types. Apollomics conducts early‐ and late‐stage clinical trials across the United States and Greater China, collaborating with research institutions and contract research organizations to accelerate patient enrollment and regulatory submissions.
Founded in 2019, Apollomics maintains dual headquarters in Shanghai and Princeton, New Jersey, reflecting its bi‐continental operating model. The company completed its initial public offering on the Nasdaq in 2020, securing capital to support ongoing clinical programs and expand its discovery engine. Apollomics leverages in‐house capabilities in medicinal chemistry, antibody engineering and translational biology, supported by manufacturing partnerships that ensure scalability of both small‐molecule and biologic candidates.
Apollomics is led by a management team with extensive experience in oncology drug development, regulatory strategy and commercial execution. The board of directors comprises industry veterans who have held leadership roles at major pharmaceutical and biotechnology companies. Together, they guide Apollomics in advancing its mission to bring next‐generation cancer therapies to patients worldwide, with a focus on delivering differentiated treatment options for underserved cancer indications.
AI Generated. May Contain Errors.
Free APLM Stock Alerts